Xofigo roll-out starts in the EU
This article was originally published in Scrip
Executive Summary
Bayer has begun the European roll-out of Xofigo (radium-223 dichloride), following its EU approval for use in patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases in mid-November (scripintelligence.com, 15 November 2013).
You may also be interested in...
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.